# Sara A. Hurvitz

Source: https://onco.cc/people/sara-hurvitz/  
OnCo record `sara-hurvitz` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sara Hurvitz is a breast cancer trialist who led DESTINY-Breast03, the trial where Enhertu beat Kadcyla.

## Summary

Sara Hurvitz is Senior Vice President and Director of the Clinical Research Division at Fred Hutchinson Cancer Center and Head of the Division of Hematology and Oncology at the University of Washington, having moved from UCLA in 2023. A breast medical oncologist specialising in HER2 and antibody-drug conjugates, she was principal investigator of DESTINY-Breast03, the trial in which trastuzumab deruxtecan was compared with trastuzumab emtansine, and of many HER2-directed and CDK4/6 studies. Her papers report the updated results of DESTINY-Breast03 in the Lancet and the KRISTINE phase 3 trial of neoadjuvant trastuzumab, pertuzumab and chemotherapy versus trastuzumab emtansine plus pertuzumab in Lancet Oncology. Her work spans HER2-positive, HR-positive and triple-negative breast cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Senior Vice President and Director, Clinical Research Division, Fred Hutchinson Cancer Center; Head, Division of Hematology and Oncology, University of Washington
- Specialisms: Breast cancer; HER2; ADCs

## Sources

- Fred Hutch faculty directory: https://www.fredhutch.org/en/faculty-lab-directory.html?q=Sara%20A.%20Hurvitz
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Hurvitz%20SA%5BAuthor%5D
- Google Scholar: https://scholar.google.com/scholar?q=Sara%20A.%20Hurvitz

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- institutions: [Fred Hutchinson Cancer Center](https://onco.cc/institutions/fred-hutch/)
- trials: [DESTINY-Breast03](https://onco.cc/trials/destiny-breast03/), [KRISTINE](https://onco.cc/trials/kristine/)
- key papers: [ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-ascent-nejm-2021/), [DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer](https://onco.cc/key-papers/paper-destiny-breast03-nejm-2022/), [NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-natalee-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/sara-hurvitz.json